Interleukin-6 and Cardioimmunology: For CMOs and CSOs

This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP), and potentially improve patient outcomes in conditions like ST-elevation myocardial infarction (STEMI) and rheumatoid arthritis (RA). The "ZEUS trial" is presented as a significant ongoing study evaluating ziltivekimab's impact on major adverse cardiovascular events in high-risk patients. The podcast balances the potential benefits of these treatments with the complexities and potential side effects of anti-inflammatory therapies, such as an increased risk of infection or gastrointestinal perforation, emphasizing the need for further research and personalized treatment approaches. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

There are no comments yet.

Please log in to write the first comment.